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Abstract
The recreational drug ecstasy [3,4-methylenedioxymethamphetamine (MDMA)], has been found to
selectively damage brain serotonin neurons in experimental animals, and probably in human MDMA
users, but detailed morphometric analyses and parallel functional measures during damage and recovery
are missing. Since there is evidence that serotonin regulates sleep, we have compared serotonergic
markers parallel with detailed analysis of sleep patterns at three time-points within 180 d after a single
dose of 15 mg/kg MDMA in male Dark Agouti rats. At 7 d and 21 d after MDMA treatment, signiﬁcant
(30–40%), widespread reductions in serotonin transporter (5-HTT) density were detected in the cerebral
cortex, hippocampus, most parts of the hypothalamus, and some of the brainstem nuclei. With the
exception of the hippocampus, general recovery was observed in the brain 180 d after treatment. Transient
increases followed by decreases were detected in 5-HTT mRNA expression of dorsal and median raphe
nuclei at 7 d and 21 d after the treatment. Signiﬁcant reductions in rapid eye movement (REM) sleep
latency, increases in delta power spectra in non-rapid eye movement sleep and increased fragmentation of
sleep were also detected, but all these alterations disappeared by the 180th day. The present data provide
evidence for long-term, albeit, except for the hippocampus, transient changes in the terminal and cellular
regions of the serotonergic system after this drug. Reduced REM latency and increased sleep fragmen-
tation are the most characteristic alterations of sleep consistently described in depression using EEG sleep
polygraphy.
Received 24 April 2007 ; Reviewed 27 July 2007 ; Revised 12 December 2007 ; Accepted 19 December 2007 ;
First published online 8 February 2008
Key words : Depression, dorsal raphe nucleus, median raphe nucleus, MDMA, REM latency,
serotonin transporter.
Introduction
‘Ecstasy’ [3,4-methylenedioxymethamphetamine
(MDMA)], an amphetamine analogue used rec-
reationally by humans, has been found to damage
brain serotonin (5-HT) neurons in experimental
animals, and reportedly, possibly also in human
MDMA users (McCann et al., 1998, 2005 ; Semple et al.,
1999).
The acute eﬀects of MDMA involve several neuro-
transmitters, e.g. monoamines and acetylcholine, but
the long-term eﬀects are selective for the serotonergic
system in the brain (Colado et al., 1999 ; Green et al.,
2003) and thus the serotonergic system might serve as
a model for selective, partial lesion of this system. In
animal models, marked reductions were observed in
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the concentration of 5-HT, 5-hydroxyindolacetic acid
and serotonin transporter (5-HTT) density (Battaglia
et al., 1987 ; Colado et al., 1993 ; Green et al., 2003 ; Sabol
et al., 1996). There is also evidence that MDMA causes
a selective loss of 5-HT axons of a particular morpho-
logical subtype, the so-called ‘ﬁne’ 5-HT ﬁbres, whilst
sparing ‘beaded’ 5-HT ﬁbres. Based mainly on
these ﬁndings, it has been proposed that MDMA is
more toxic to 5-HT projection neurons in the dorsal
raphe nucleus (DRN) than those in the median raphe
nucleus (MRN) (Molliver et al., 1989 ; O’Hearn et al.,
1988). However, expression of 5-HTT mRNA in the
raphe nuclei has not been examined; consequently,
direct comparisons of responses of dorsal and other
raphe nuclei have not been measured.
5-HT plays a key role in the regulation of sleep,
especially rapid eye movement (REM) sleep (Portas
et al., 1996). Initiation and duration of REM sleep is
modulated by the serotonergic system (Adrien, 2002;
Portas et al., 1996). Increase in extracellular 5-HT con-
centration by 5-HT releasers, 5-HT reuptake blockers
or several 5-HT receptor agonists may increase REM
latency (Monti and Monti, 1999 ; Sommerfelt and
Ursin, 1991; Ursin, 2002). Preclinical studies involving
pharmacological depletion or anatomical lesions of
5-HT neurons have generally shown changes in
REM and non-rapid eye movement (NREM) sleep.
However, most of these preclinical studies involved
massive depletions of 5-HT with sleep studies gener-
ally performed shortly after lesioning (Allen et al.,
1993 ; Koella et al., 1968 ; Touret et al., 1991).
The present study was designed to characterize
MDMA-induced damage and recovery of the sero-
tonergic system including both cellular and terminal
events. Furthermore, we hypothesized that long-
lasting partial damage and recovery of this systemwill
be manifested in changes of sleep parameters. For
these purposes we investigated parallel changes in
5-HTT mRNA expression in two raphe nuclei, 5-HTT
ﬁbre densities in several brain areas, and 16 functional
measures of sleep in response to MDMA adminis-
tration at three time-points within 180 d.
Method
Animals
All animal experiments were carried out in accordance
with the European Communities Council Directive of
24 November 1986 (86/609/EEC) and the National
Institutes of Health Principles of Laboratory Animal
Care (NIH Publications No. 85-23, revised 1985),
as well as speciﬁc national laws (the Hungarian
Governmental Regulation about Animal Studies,
31 December 1998). Permission was also obtained
from the local ethical committees. Male Dark Agouti
rats aged 7 wk (Harlan, Olac Ltd, Shaw’s Farm,
Blackthorn, Bicester, Oxon, UK) were used in the
experiments. The animals (four per cage) were kept
under controlled environmental conditions (tempera-
ture 21¡1 xC, and a 12 h light–dark cycle, lights on at
06 :00 hours). Standard food and drinking water were
freely available.
Drug administration and treatment protocol
(¡)3,4-Methylenedioxymethamphetamine hydrochlo-
ride (MDMA, certiﬁed reference compound, purity
>99.5%) was kindly provided by Professor
Istvan Hermecz (Sanoﬁ-Synthelabo-Chinoin, Budapest,
Hungary). The drug was dissolved in 0.9% NaCl at
a dose equivalent to 15 mg/kg free base and was
injected intraperitoneally in a volume of 1 ml/kg.
Control animals received an injection of 0.9% NaCl in
a volume of 1 ml/kg. To measure the time-course of
5-HTT mRNA expression after MDMA treatment,
in-situ hybridization histochemistry was performed
3, 7, 21 and 180 d after drug treatment (n=48, six
animals in each control and treated group at the four
time-points). In parallel, the density of serotonergic
ﬁbres was assessed in separate group of rats using
5-HTT immunohistochemistry (n=5–6 per group).
Separate groups of animals were used for vigilance
studies (n=6–9 per group).
In-situ hybridization histochemistry
In-situ hybridization was performed as previously
described (Hansson et al., 1998 ; Kovacs et al., 2007).
After hybridization, sections were exposed to a
BAS-MS 2340 Imaging Plate (FujiPhotoFilm Co. Ltd,
Tokyo, Japan) for 6–13 d, depending on the intensity
of the hybridization signal. The hybridization signals
were quantiﬁed with ImageJ 1.32j imaging software
(Wayne Rasband, NIH, Bethesda, MD, USA). For
quantiﬁcation, we averaged 9–9 sections for the
DRN (betweenx9.30 andx7.30 mm from the level of
bregma) and 8–8 for the MRN (between x8.30 and
x7.30 mm from the level of bregma) per animal. The
exact topography of these regions was determined
according to a conventional rat brain atlas (Paxinos
and Watson, 2005). The mean grey values over the
DRN or MRN were measured on the ﬁlm autoradio-
graph, and also over a similar size of the surrounding
area that did not contain serotonergic cells. Diﬀerences
measured in grey density were used for evaluation
and statistical analysis.
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To obtain more precise measures for the eﬀects of
MDMA, 5-HTT mRNA expression of individual cells
was counted. The sections were coated with nuclear
track emulsion (NTB-2, Kodak, Rochester, NY, USA)
for 4 wk at 4 xC. For each experimental animal, 4–4
sections were analysed, and the number of silver
grains was measured over serotonergic cell bodies
(25 or 10 cells in the DRN and MRN, in each section,
respectively). The threshold was adjusted to the back-
ground signal level, the area in question was selected
and the mean grey density was automatically calcu-
lated with respect to the surface area of the selected
section. The mean grey density values reﬂect the
mRNA expression of the cell.
Immunohistochemistry
The animals were deeply anaesthetized with nem-
butal, and perfused transcardially with Zamboni
ﬁxative solution. Brains were removed and post-ﬁxed
overnight at 4 xC in ﬁxing solution. Free-ﬂoating
40-mm-thick coronal sections were cut using a freezing
microtome. The presence of 5-HTT was detected using
a 1:3000 dilution of a rabbit polyclonal anti-5-HTT
antibody (Oncogene, San Diego, CA, USA). Immuno-
staining was developed with a peroxidase/DAB kit
(EnVisionTM, Dako, Glostrup, Denmark).
Monochrome digital images were made using
similar light microscopic settings (Olympus BX51,
objective, aperture, exposure time) at r40 magniﬁ-
cation. Four to six representative, non-overlapping
photographs were taken in each anatomical region:
hippocampus (dentate gyrus, CA1, CA2, CA3)
(3.60–3.20 mm caudal to bregma), hypothalamus
(posteroventral preoptic areas (0.30–0.40 mm), lateral
hypothalamic area (3.60–3.20 mm), posterior hypo-
thalamic nucleus (3.60–4.30 mm), paraventricular
nucleus (1.50–2.10 mm), suprachiasmatic nucleus
(SCN) (0.90–1.40 mm), tuberomamillary nucleus
(3.80–4.00 mm), cerebral cortex layers I–II [somato-
sensory and somatomotor cortex (3.30–2.30 mm)],
periaqueductal grey [ventrolateral and dorsomedial
part (7.80–8.30 mm)], peripeduncular tegmental
nucleus (7.80–8.30 mm) and medial pontine reticular
formation (8.80–7.80 mm).
Quantitative analysis of serotonergic ﬁbre density
was performed using analySIS image software (Soft
Imaging System GmbH, Lakewood, CO, USA). The
positively stained ﬁbres were distinguished from the
background by means of density thresholding, and the
area occupied by immunostained ﬁbres was deter-
mined and recorded as a percentage of the total image
area.
Vigilance studies
Surgery
Animals were chronically equipped with electro-
encephalogram (EEG) and electromyogram (EMG)
electrodes, as described previously (Filakovszky et al.,
2001 ; Kantor et al., 2002). Surgery was performed
under halothane (2%) anaesthesia (Fluotec 3) using
Kopf stereotaxic instrument. After a 10-d recovery
period, the rats were attached to the polygraph by a
ﬂexible recording cable and an electric swivel, ﬁxed
above the cages, permitting free movement of the
animals. To habituate the animals to the recording
conditions, the rats were attached to the polygraph
and received intraperitioneal injections of physio-
logical saline daily for 5 d before the experiments.
Sleep recording and scoring
EEG, EMG and motor activity were recorded for 24 h
periods, starting at light onset as described earlier
(Gottesmann, 1992 ; Kantor et al., 2002). The vigilance
states were scored visually for 4-s periods for the
ﬁrst 2 h after light onset using conventional criteria
(Kantor et al., 2002, 2004). The polygraphic recordings
were classiﬁed by sleep analysis software for the
24-h recordings (SleepSign for Animal, Kissei Comtec
America Inc.). EEG power spectra were computed
for consecutive 4-s epochs at the frequency range
of 0.25–30 Hz (fast Fourier transformation routine,
Hanning window; frequency resolution, 0.25 Hz)
(Kantor et al., 2002, 2005).
The sleep variables were divided into four groups:
REM and NREM [light slow-wave sleep (SWS-1) plus
deep slow-wave sleep (SWS-2)] sleep indexes, wake
parameters before and at around activity (dark) onset
and sleep continuity. The REM sleep parameters
included REM latency [the time elapsed from sleep
onset until the ﬁrst seven consecutive epochs of REM
sleep (Mendelson, 1996), duration of REM in the ﬁrst
hour (calculated from the beginning of light onset),
time of REM maximum (the hour in which the most
REM sleep occurred) and the sum of REM in the light
period, the passive phase (sum of duration of all REM
sleep periods during 0–12 h)]. NREM sleep indexes
included NREM latency [the time elapsed between
light onset and the ﬁrst consecutive NREM sleep
episode lasting at least 3 min, and not interrupted by
more than 14 consecutive 4-s epochs, or a cumulated
total of 240 s not scored as NREM sleep (Deboer et al.,
2003 ; Huber et al., 1998). NREM sleep in the ﬁrst and
second hour (duration of NREM phase was calculated
from light onset), SWS-1 and SWS-2 latencies (the time
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between light onset and the ﬁrst cumulated total of a
minimum 28 s of SWS-1 or SWS-2), sum of SWS-1 and
SWS-2 in the light period (duration of all SWS-1 and
SWS-2 sleep periods during 0–12 h)]. Quantitative
analysis of NREM sleep, namely EEG power spectra of
SWS-1 and SWS-2 were also performed as described
above (Kantor et al., 2004).
The wake parameters around activity onset were
the activity onset (deﬁned as the hour when the
duration of active wake increased by a minimum of
50% compared to the average in the passive phase)
and the passive wake before activity onset (duration of
passive wake during the hour preceding the activity
onset). Sleep continuity was deﬁned as the sum of the
number of awakenings (either active wake or passive
wake) that disconnected any sleep periods [SWS-1,
SWS-2, intermediate stage of sleep (IS), or REM]
during the light period, the passive phase (0–12 h).
Statistical methods
Statistica 7.0 software (Statsoft Inc., Tulsa, OK, USA)
was used for statistical analysis. Morphological data
and REM, NREM, SWS-1 and SWS-2 latencies, the sum
of REM, SWS-1 and SWS-2 in the light period, passive
wake before activity onset and the fragmentation
of sleep were analysed using one- or two-way (treat-
ment and time) analysis of variance (ANOVA) and
Newman–Keuls test for post-hoc comparisons. REM
sleep in the ﬁrst hour and NREM sleep in the ﬁrst
and second hour were also evaluated by multi-
variate analysis of variance (MANOVA) for repeated
measures. In the case of time of REM maximum
and activity onset the Mann–Whitney U test was
performed. Log-transformed values were used for the
statistical analysis of the EEG power spectra data.
Results
5-HTT mRNA expressions in the dorsal and median
raphe nuclei
Dorsal raphe nucleus
The changes in 5-HTT mRNA expression density were
quantiﬁed by ﬁlm autoradiography at each time-point
studied (3, 7, 21 and 180 d after MDMA treatment)
(Figure 1a, b). Alterations in 5-HTT mRNA expression
were further analysed on slides dipped into auto-
radiographic emulsion (Figure 2a). The levels of
5-HTT mRNA in the DRN between groups are shown
in the autoradiographs in Figure 1(a). In general,
signiﬁcant treatmentrtime interaction (F3,40=6.369,
p=0.001) was found for this parameter. A signiﬁcant
increase was observed 7 d after drug administration
(+24%, p<0.01) (Figure 1a).
To obtain more sensitive measures for the eﬀects
of MDMA, 5-HTT mRNA expression of individual
cells was counted at 7 and 21 d after drug or saline
treatment (Figure 3). We noted signiﬁcantly elevated
5-HTT mRNA expression at 7 d (+53%, p<0.05)
(Figures 2a, 4a, c) and signiﬁcantly reduced 5-HTT
mRNA expression at 21 d after MDMA treatment
(x22%, p<0.05) (Figures 2a, 4e, g).
MDMA did not aﬀect the levels of 5-HTT mRNA in
the DRN compared to the control group at 3 and 180 d
after drug exposure (Figure 1a, b).
Median raphe nucleus
In the MRN, 5-HTT mRNA density was quantiﬁed by
ﬁlm autoradiography at each survival time (3, 7, 21
and 180 d after MDMA treatment) (Figure 1a, c), and
the changes in 5-HTT mRNA expression were further
compared by analysis of the signal from the slides
dipped into autoradiographic emulsion, similar to the
measurements on the DRN (Figure 2b). In general,
signiﬁcant treatmentrtime interaction (F3,39=4.790,
p=0.006) was found in the MRN. As shown in Figure
1(c), 5-HTT mRNA expression signiﬁcantly decreased
21 d (x27%, p<0.05) after drug exposure in the MRN.
To support these results by a more sensitive method,
5-HTT mRNA expression of individual cells was
counted 7 and 21 d after MDMA administration.
We found signiﬁcant increase in the levels of 5-HTT
mRNA at 7 d (+43%, p<0.05) (Figures 2b, 4b, d) and
signiﬁcant decrease at 21 d after MDMA treatment
(x18%, p<0.05) (Figure 2b, 4f, h). No diﬀerences
between controls and treated animals were observed
at 3 and 180 d after MDMA administration (Figure 1a,
c). Qualitatively, all of these eﬀects were similar to the
changes observed in the DRN.
Density of 5-HTT immunoreactive ﬁbres in the brain
Cerebral cortex
Treatment with MDMA signiﬁcantly reduced 5-HTT
ﬁbre density at 7 and 21 d in the somatosensory
(treatment eﬀect : F1,28=37.791, p<0.0001; Figure 5a–d)
and somatomotor cortex (treatment eﬀect : F1,28=
74.456, p<0.0001; Table 1). Signiﬁcant treatmentr
time interaction was observed in the somatomotor
cortex (F2,56=6.665, p=0.0025). The percentage
changes in the somatosensory cortex and somato-
motor cortex were similar : x31%, x33%, x15%,
and x36%, x32%, x14%, at 7, 21 and 180 d after
treatment, respectively. The reduction in 5-HTT ﬁbre
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density was not signiﬁcant 180 d after drug exposure
(Figure 5e).
Hippocampus
In the hippocampus, we found an overall decrease in
the 5-HTT ﬁbre density, which was present from day 7
up to day 180 after treatment (Table 1). We observed
signiﬁcant decreases in all hippocampal areas exam-
ined (CA1 treatment eﬀect : F1,28=27.012, p<0.0001;
CA2 treatment eﬀect : F1,28=57.202, p<0.0001 ; CA3
treatment eﬀect : F1,28=48.173, p<0.0001), except for
the dentate gyrus. Post-hoc tests indicated signiﬁ-
cantly reduced 5-HTT ﬁbre density in the CA1
at all time-points examined (x26%, x37%, x36%)
(Figure 5f–j), CA2 (x35%, x41%, x32%) and CA3
(x33%, x46%, x31%) at 7, 21 and 180 d after
treatment, respectively. A reduction in 5-HTT ﬁbre
density was also noted in the dentate gyrus but this
change was not signiﬁcant (x24%, x35%, x19%, at
7, 21 and 180 d after treatment, respectively).
Hypothalamus
The eﬀects of MDMA on 5-HTT ﬁbre density were
diﬀerent in diﬀerent hypothalamic nuclei and areas
(Table 1). Reduced 5-HTT ﬁbre density was found
in the posterior hypothalamic nucleus (treatment
eﬀect : F1,27=32.256, p<0.0001), SCN (treatment eﬀect :
F1,27=30.423, p<0.0001) and tuberomamillary nucleus
(treatment eﬀect : F1,27=35.121, p<0.0001) ; the lateral
hypothalamic area ; posteroventral preoptic areas and
the paraventricular nucleus were resistant to MDMA
at all time-points measured. Alterations in 5-HTT
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Figure 1. Expression of 5-HTTmRNA in control (saline) rats, and in rats at 3, 7, 21 and 180 d after treatment with a single dose of
MDMA (15 mg/kg). (a) Representative autoradiographic coronal sections through the dorsal raphe nucleus (black arrowhead,
i) and median raphe nucleus (white arrowhead,f) after in-situ hybridization. Eﬀects of MDMA on 5-HTT mRNA expression
density in (b) the dorsal raphe nucleus and (c) the median raphe nucleus in rats exposed to MDMA 3, 7, 21, 90 and 180 d earlier.
5-HTT mRNA is expressed as a relative ratio compared to controls (%). Data are mean¡S.E.M. (n=6). * Signiﬁcantly diﬀerent
compared to the saline group (p<0.05).
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ﬁbre density were as follows: lateral hypothalamic
area (x12%, x19%, x8%) ; posterior hypothalamic
nucleus (x22%,x38%,x30%) ; SCN (x30%,x35%,
x17%); tuberomamillary nucleus (x19%, x35%,
x23%); posteroventral preoptic areas (x11%, x17%,
x2%); paraventricular nucleus (x2%,x6%,x3%), at
7, 21 and 180 d after MDMA, respectively.
Brainstem
In general, changes in the brainstem were smaller, and
signiﬁcant alterations were observed only in two re-
gions : the ventrolateral cell groups (treatment eﬀect :
F1,27=16.452, p=0.0004) and dorsomedial cell groups
(treatment eﬀect : F1,27=15.212, p=0.0006) of the peri-
aqueductal grey matter in the midbrain, but only at
21 d (Table 1). The eﬀects of MDMA on 5-HTT ﬁbre
density in the peripeduncular tegmental nucleus and
the medial part of the pontine reticular formation were
not signiﬁcant at any time-point studied. Post-hoc
comparison revealed the following changes in 5-HTT
ﬁbre density : periaqueductal central grey ventro-
lateral part (x15%, x30%, x15%) ; periaqueductal
central grey dorsomedial part (x17%,x36%,x16%);
peripeduncular tegmental nucleus (x7%, x12%,
x7%) ; medial pontine reticular formation (x3%,
x14%, x5%), at 7, 21 and 180 d after treatment, re-
spectively.
Eﬀects of MDMA on sleep parameters
REM sleep
Complete 24 h recordings of REM sleep are shown
in Figure 6(a–c). In addition, four parameters, REM
latency, REM in the ﬁrst hour of passive phase,
time of REM maximum and the sum of REM in
the light period (passive phase) were measured and
calculated for the characterization of onset and
duration of REM sleep (Table 2). Signiﬁcant decreases
in REM latency were detected at 7 and 21 d after
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Figure 2. Quantiﬁcation of 5-HTT mRNA expression by
measuring grain density in individual cells of (a) the dorsal
raphe nucleus and (b) the median raphe nucleus at 7 and 21 d
after MDMA treatment. Values represent mean grain
density/cell ratio relative to controls. Data are mean¡S.E.M.
(n=6). * Signiﬁcantly diﬀerent compared to the control
(saline) group (p<0.05).
(a)
(b)
Figure 3. Bright-ﬁeld image showing the cellular localization
of 5-HTT mRNA in the dorsal raphe nucleus in (a) control
rats, and (b) in rats 21 d after treatment with a single dose of
MDMA. Panel (b) shows decreased grain density. Scale bars,
25 mm.
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MDMA administration (treatment eﬀect : F1,36=22.880,
p<0.0001). Changes in REM latency were x55%,
x53%, and x29%, at 7, 21 and 180 d after MDMA,
respectively. In parallel, increased duration of REM
(+245%) was found in the ﬁrst hour of the passive
phase 21 d after MDMA (treatment eﬀect : F1,46=7.689,
p=0.0079). Duration of REM sleep analysed during
the whole light period (x15%,x34%,x15%, at 7, 21
and 180 d after treatment, respectively) was not
signiﬁcantly aﬀected by MDMA treatment. The time
of actual maximum of REM sleep was not signiﬁcantly
altered (+64%,+30%, x9%, at 7, 21 and 180 d after
MDMA, respectively). At 7 d, some MDMA-treated
animals showed an extreme time-course of REM
during the passive phase ; REM activity showed a
biphasic pattern, with the higher peak occurring very
late, close to the dark phase (Figure 6a).
NREM sleep
Nine parameters (NREM latency, NREM in ﬁrst and
second hour, SWS-1 and SWS-2 latency, delta power
SWS-1 and SWS-2 in a 2-h recording period beginning
at light onset and the sum of SWS-1 and SWS-2 in the
light period) were measured and calculated for the
characterization of onset, duration and quality of
NREM sleep (Table 2 ; Figure 7). Diﬀerences in NREM
latency were not signiﬁcant at any time-point (x13%,
x15%, 0%, at 7, 21 and 180 d after treatment, re-
spectively). Neither SWS-1 (+8%, x51%, 3%, at 7,
21 and 180 d after treatment, respectively) nor SWS-2
latencies (x2%, x6%, 1%, at 7, 21 and 180 d after
treatment, respectively) were signiﬁcantly altered by
the drug. None of the parameters used for character-
ization of duration of NREM, NREM in the ﬁrst hour
(+28%,+58%,+21%, at 7, 21 and 180 d after treat-
ment, respectively) and second hour (x10%, x4%,
0%, at 7, 21 and 180 d after treatment, respectively)
were altered by MDMA at any time-point studied.
Signiﬁcant decreases in the sum of SWS-1 in the whole
light period were found 21 d after MDMA treatment
(treatmentrtime interaction: F2,40=4.847, p=0.013;
+8%,x51%,x3%, at 7, 21 and 180 d after treatment,
respectively). Delta power measured either in SWS-1
or in SWS-2 was increased by MDMA at both 7 and
21 d after treatment (Figure 7a, b, d, e). Changes in the
lower frequencies (1 Hz and 2 Hz) were even more
consistent. Interestingly, at day 7, the increase in delta
power was more pronounced in SWS-1; the increase
shiftedmainly to SWS-2 at 21 d (Figure 7a, e). In control
rats, SWS-2 latency (time eﬀect : F2,42=10.815, p=
0.00016) was increased and the sum of SWS-2 (time
eﬀect : F2,40=28.235, p<0.0001) in the light period was
decreased in the old animals.
Wake parameters around activity onset
Activity onset preceding the active phase was deter-
mined for each animal, in each experimental group. In
general, activity was increased by 50% compared to
the preceding 8-h resting period 2–3 h before lights
oﬀ. No signiﬁcant MDMA eﬀect was found for this
(a) (b)
(c) (d)
(e) (f)
(g) (h)
Figure 4. Dark-ﬁeld images show 5-HTT mRNA expression
in the dorsal raphe nucleus (a, c, e, g) and median raphe
nucleus (b, d, f, h) in control (a, b, e, f ) rats and in rats treated
with MDMA 7 d (c, d) and 21 d (g, h) earlier. 5-HTT mRNA
revealed by in-situ hybridization with a 35S-labelled
ribonucleotide probe. Increased 5-HTT mRNA expression at
7 d following a single dose of MDMA (c, d), compared to
controls (a, b). A marked decrease in 5-HTT mRNA is shown
in panels (g) and (h) at 21 d following a single dose of MDMA
compared to controls (e, f ). Scale bars : (a, c, e, g), 100 mm;
(b, d, f, h), 50 mm.
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parameter (+17%, 0%, 0%, at 7, 21 and 180 d after
treatment, respectively). Duration of passive wake
during the hour preceding the activity alteration was
also calculated. Changes in the duration of passive
wake before activity onset were+5%, x28%, x21%,
at 7, 21 and 180 d after treatment, respectively. None of
these parameters were signiﬁcantly altered by MDMA
treatment (Table 2).
Sleep continuity
The number of wake periods during the 12-h passive
phase was used to characterize sleep continuity.
(a) (b) (c) (d) (e)
(f) (g) (h) (i) (j)
Figure 5. 5-HTT immunoreactive axons in the somatosensory cortex and in the hippocampal CA1 region. Representative
photomicrographs illustrating the areas where the densitometry was applied [open rectangles in panels (a) and (f)], and 5-HTT
ﬁbre density in control (b, g) and MDMA-treated rats at 7 d (c, h), 21 d (d, i) and 180 d (e, j) after treatment. Decreases in
5-HTT ﬁbre density can be observed in panels (c, d, h, i). Scale bars, 20 mm.
Table 1. 5-HTT ﬁbre density at 7, 21 and 180 d after MDMA (15 mg/kg) treatment in brain areas of Dark Agouti rats
7 d 21 d 180 d
Saline MDMA Saline MDMA Saline MDMA
Cerebral cortex
Somatosensory cortex 6.92¡0.26 4.76¡0.35* 6.02¡0.33 4.05¡0.18* 6.31¡0.27 5.36¡0.40
Somatomotor cortex 7.17¡0.38 4.61¡0.16* 6.27¡0.31 4.29¡0.28* 6.28¡0.18 5.41¡0.32
Hippocampus
CA1 6.33¡0.47 4.67¡0.19* 4.91¡0.52 3.09¡0.23* 4.48¡0.55 2.87¡0.28*
CA2 7.08¡0.16 4.64¡0.36* 5.79¡0.20 3.43¡0.27* 5.37¡0.67 3.65¡0.28*
CA3 6.07¡0.25 4.09¡0.25* 6.09¡0.28 3.30¡0.60* 4.79¡0.43 3.31¡0.33*
Dentate gyrus 2.78¡0.18 2.10¡0.20 2.81¡0.20 1.81¡0.11 2.80¡0.36 2.28¡0.24
Hypothalamus
Posteroventral preoptic areas 5.88¡0.49 5.23¡0.48 5.52¡0.44 4.57¡0.19 4.91¡0.58 4.80¡0.25
Lateral hypothalamic area 6.38¡0.48 5.60¡0.43 4.96¡0.18 4.03¡0.36 5.47¡0.29 5.04¡0.32
Posterior hypothalamic nucleus 6.71¡0.30 5.24¡0.31* 6.25¡0.51 3.89¡0.40* 4.52¡0.39 3.18¡0.30*
Paraventricular nucleus 5.43¡0.27 5.29¡0.46 6.08¡0.38 5.72¡0.52 5.84¡0.29 5.68¡0.27
Suprachiasmatic nucleus 6.78¡0.33 4.76¡0.34* 5.53¡0.46 3.60¡0.19* 4.84¡0.43 4.01¡0.28
Tuberomamillary nucleus 5.90¡0.19 4.78¡0.31* 5.95¡0.36 3.86¡0.33* 5.21¡0.37 4.02¡0.22*
Brainstem
Peripeduncular tegmental nucleus 4.70¡0.12 4.38¡0.28 4.12¡0.25 3.63¡0.33 3.93¡0.17 3.65¡0.46
Medial pontine reticular formation 4.23¡0.32 4.09¡0.35 2.93¡0.29 2.52¡0.32 3.22¡0.30 3.07¡0.38
Periaqueductal central grey
Ventrolateral part 10.34¡0.29 8.82¡0.39 8.28¡0.43 5.83¡0.42* 6.66¡0.54 5.64¡0.71
Dorsomedial part 9.53¡0.71 7.92¡0.58 8.74¡0.60 5.61¡0.33* 7.73¡0.70 6.47¡0.77
Data are presented as mean¡S.E.M. of 5–6 animals per group.
* Signiﬁcantly diﬀerent compared to the relevant control (saline) group (p<0.05).
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MDMA caused signiﬁcant increase in this parameter
but only at day 7 (+83%,+12%, x32%, at 7, 21 and
180 d after treatment, respectively) (Table 2). The
treatmentrtime interaction (F2,41=7.306, p=0.0019)
was signiﬁcant.
Discussion
Parallel measurements of 5-HTT mRNA expression in
the two raphe nuclei, 5-HTT ﬁbre density in several
brain areas, and more than a dozen functional
measures of sleep at three time-points within 180 d
after MDMA administration allowed us to compare
sleep disturbance with morphometric data and func-
tions of raphe nuclei during a long period of time
when the brain serotonergic system was damaged or
partially recovered.
Acute and subacute eﬀects of MDMA on sleep have
been previously described by our group (Balogh et al.,
2004). Here we concentrated on chronic and persistent
morphological and functional eﬀects of the drug.
In the present study, 5-HTT mRNA expression
was measured in the two largest groups of ascending
projecting serotonergic neurons, the DRN and the
MRN. A transient increase followed by a transient
decrease and a complete recovery were found during
the 180-d period in both raphe nuclei studied. The
eﬀects of MDMA on 5-HTT mRNA expression in
DRN and MRN did not diﬀer in time or extent. The
up-regulation of 5-HTT mRNA expressions 7 d after
MDMA treatment in both raphe nuclei may be ex-
plained by a compensatory phenomenon following
decreased axonal transport or a possible distal down-
regulation of the expression of 5-HTT (Kovacs et al.,
2007).
In addition, 5-HTT ﬁbre density was also measured
in a number of brain regions. Decreases were detected
in several brain areas, from the brainstem up to the
cerebral cortex at 7 and 21 d. Evidence for partial
recovery was found in most aﬀected brain regions,
except for the hippocampus, by 180 d.
It is well established for several species (Hornung
et al., 1990 ; Kosofsky and Molliver, 1987 ; Mulligan
and Tork, 1988) that the cerebral cortex contains at
least two major types of 5-HT ﬁbres. It was suggested
that the ﬁne ﬁbres are derived from the DRN, while
thicker ﬁbres are derived from the MRN (Kosofsky
and Molliver, 1987 ; Mulligan and Tork, 1988). It has
been reported previously that the ﬁne serotonergic
ﬁbres are selectively vulnerable to a number of
amphetamine derivatives (Mamounas and Molliver,
1988 ; O’Hearn et al., 1988). However, later neuro-
anatomical and biochemical studies suggest that
DRN selectivity of these amphetamines may not be
exclusive (Haring et al., 1992 ; Hensler et al., 1994 ;
Mamounas and Molliver, 1988; McQuade and Sharp,
1995 ; O’Hearn et al., 1988). Data obtained from these
studies are in accordance with the observation that
ﬁne ﬁbres arise from both raphe nuclei (Morin and
Meyer-Bernstein, 1999). Our immunohistochemical
data support the conclusion that axons of MRN origin
are also aﬀected by MDMA. The origin of serotonergic
projections to the SCN is almost exclusively the MRN
(Glass et al., 2003 ; Meyer-Bernstein et al., 1999), and
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Figure 6. Twenty-four-hour recordings of rapid eye
movement (REM) sleep in MDMA-treated (- -m- -) and
saline-treated (–&–) animals at 7 d (a), 21 d (b) and 180 d
(c) after treatment. Each point represents mean values¡S.E.M.
(n=6–8) of the time spent in REM sleep within each hour.
* Signiﬁcantly diﬀerent compared to the saline group
(p<0.05).
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MRN median raphe ﬁbres project heavily throughout
the entire hippocampus (Azmitia and Segal, 1978;
Conrad et al., 1974 ; Imai et al., 1986 ; Vertes and
Martin, 1988). The SCN and the three CA areas of the
hippocampus were strongly aﬀected by MDMA in our
experiment. Furthermore, changes in 5-HTT mRNA
expression in the DRN and MRN were similar in
the present study. These data support the view that
axons of both DRN and MRN origin are temporarily
damaged by the drug.
Recovery of serotonergic neurons was observed in
animals treated with a single dose of MDMA 180 d
previously in most areas examined except for the
hippocampus. This observation supports previous
results that the rate and degree of recovery is region
dependent (Sabol et al., 1996). Scanzello et al. (1993)
found that the hippocampus is the only brain region
where none of the presynaptic 5-HT neuronal markers
recovered 1 yr after MDMA administration.
Our results support previous data showing that the
hippocampus is more resistant to recovery compared
to other brain regions. The explanation for this might
be the speciﬁc hierarchy of hippocampal neurons
and/or alteration of synthesis or metabolism of neuro-
trophic factors (Martinez-Turrillas et al., 2006). Among
the consequences of these ﬁndings might be long-term
changes in memory functions and/or anxiety. Indeed,
human studies most consistently point to cognitive
and memory disturbances in current and previous
ecstasy users (Morgan, 2000 ; Parrott, 2001).
A selective decrease in REM latency was found at
7 and 21 d after MDMA administration. Similarly, an
increase in the amount of REM was found in the ﬁrst
hour. None of the other parameters characterizing
REM sleep were altered. Our data support the view
that initiation of REM sleep is modulated by the
serotonergic system (Adrien, 2002 ; Bhatti et al., 1998;
Portas et al., 1996). In contrast, none of the other REM
sleep parameters nor most of the NREM sleep par-
ameters were aﬀected by the temporary lesion of the
serotonergic system in our study. It has been sug-
gested that higher amounts of REM sleep, described in
5-HTT knockout mice (Alexandre et al., 2006 ; Wisor
et al., 2003) result from excessive serotonergic tone
during early life (Alexandre et al., 2006). Our data
support this notion, because a transient decrease of
Table 2. Sleep parameters at 7, 21 and 180 d after MDMA (15 mg/kg) treatment
Sleep parameter
7 d 21 d 180 d
Saline MDMA Saline MDMA Saline MDMA
REM sleep
REM latency (s) 3745¡446 1676¡249* 2937¡364 1383¡160* 3511¡647 2485¡451
REM in 1st hour (s) 53.0¡26.9 128.4¡41.1 44.0¡22.6 152.0¡40.3* 8.0¡5.3 15.6¡7.8
Time of REM max (h) 4.88¡0.97 8.00¡1.11 4.71¡0.97 6.13¡0.58 6.88¡0.79 6.25¡0.90
Sum of REM in the light period (s) 2485¡684 2107¡429 3742¡1277 2453¡458 3465¡660 2959¡766
NREM sleep
NREM latency (s) 1798¡367 1558¡269 1986¡412 1687¡515 2201¡394 2195¡429
NREM in ﬁrst hour (s) 1107¡217 1414¡167 891¡127 1410¡248 663¡144 801¡179
NREM in second hour (s) 2230¡196 1998¡113 2280¡188 2188¡157 2136¡95 2133¡122
SWS-1 latency (s) 1585¡395 1717¡250 1528¡458 746¡225 2008¡254 2064¡315
SWS-1 delta power ( mV2/Hz) 3218¡254 4874¡588* 3066¡139 3461¡87 2602¡205 2527¡456
Sum of SWS-1 in the light period (s) 7259¡751 6910¡1139 8222¡770 4444¡287* 10751¡1076 12473¡1071
SWS-2 latency (s) 1993¡465 1962¡228 2208¡425 2069¡461 3578¡358 3610¡302
SWS-2 delta power ( mV2/Hz) 8813¡1230 12005¡1394 7255¡632 11478¡1108* 4727¡321 5313¡723
Sum of SWS-2 in the light period (s) 16779¡1400 18502¡1523 16336¡996 20180¡591 10776¡872 9738¡1510
Wake parameters around activity onset
Activity onset (h) 9.38¡0.19 11.00¡0.72 9.67¡0.21 9.63¡0.42 10.38¡0.60 10.38¡0.53
Passive wake before activity onset (s) 501.5¡87.5 528.6¡128.2 604.0¡82.8 435.5¡77.5 611.5¡141.1 483.5¡111.1
Sleep continuity
Number of wakes in the light period 209.6¡20.1 384.1¡42.1* 228.6¡35.0 255.8¡35.8 176.4¡28.9 119.8¡13.9
REM, Rapid eye movement ; NREM, non-rapid eye movement ; SWS-1, light slow-wave sleep ; SWS-2, deep slow-wave sleep.
Data are presented mean¡S.E.M. of 7–9 animals per group.
* Signiﬁcantly diﬀerent compared to the saline group (p<0.05).
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5-HTT expression together with decreased 5-HT
availability observed 21 d after MDMA treatment
failed to cause a general enhancement in the amount
of REM sleep. Increase in REM sleep was restricted to
the ﬁrst hour of passive phase suggesting that it was
caused solely by a decrease in REM latency.
MDMA administration is followed by depletions in
5-HTT ﬁbre density in some, but not all, brain areas
involved in the regulation of REM sleep examined in
this study. Signiﬁcant damage was found in the SCN
and tuberomamillary nucleus, parallel with reduced
REM latency at 7 and 21 d after MDMA treatment.
In contrast, we could not ﬁnd signiﬁcant changes in
5-HTT density around the ‘eﬀector’ neurons located in
the medial pontine reticular formation (Sinton and
McCarley, 2004) and the peripeduncular tegmental
nucleus (Adrien, 2002) in the brainstem, thus, it is
unlikely, that the observed decrease in REM latency
could be a consequence of changes in the serotonergic
system of these areas.
The decrease in REM latency induced by MDMA
may be explained by a decreased inhibition of SCN
by 5-HT, and consequently an earlier activation of
SCN. 5-HT inhibits the spontaneous discharge of SCN
neurons in vivo and in hypothalamic slices in vitro (Yu
et al., 2001). This eﬀect may be mediated via 5-HT7 and
(a) 7 d (d) 7 d
(b) 21 d (e) 21 d
(c) 180 d (f) 180 d
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Figure 7. EEG power spectra (absolute power density) in slow-wave sleep (SWS)-1 (a–c) and SWS-2 phase (d–f ) at 7 d (a, d), 21 d
(b, e), and 180 d (c, f ) after MDMA treatment. Each point represents mean values¡S.E.M. (n=8) of 1 Hz bins in a 2-h recording
period beginning at light onset. * Signiﬁcantly diﬀerent compared to the saline group (p<0.05). –&–, Sal ; - -m- -, MDMA.
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5-HT1B receptors (Yannielli and Harrington, 2004 ; Yu
et al., 2001). The SCN strongly promotes REM sleep
tendency during the rest phase, and the SCN neurons
show increased activity during REM sleep compared
to NREM sleep, the peak of the ﬁring rate of SCN is
in the middle of the passive phase when the amount
of REM sleep is the highest during the day (Deboer
et al., 2003 ; Wurts and Edgar, 2000). In conclusion,
the decrease in 5-HTT ﬁbre density in the SCN could
be one possible explanation for decreased REM
latency.
The importance of our ﬁndings is further supported
by the fact that disturbances of sleep are typical
for most depressed patients and belong to the core
symptoms of depression according to DSM-IV criteria
(Riemann et al., 2001). More than 90% of depressed
patients complain about disturbances in sleep quality
(Mendelson et al., 1977 ; Riemann et al., 2001).
Diﬃculties in falling asleep, frequent nocturnal awak-
enings, and early morning awakening are the most
frequent complaints, and reduced REM latency and
increased sleep fragmentation are the most character-
istic alterations described in depression using EEG
sleep polygraphy (Riemann et al., 2001). MDMA has
been shown to disrupt the circadian cycle in vivo and
ﬁring patterns of SCN in hypothalamic slices (Balogh
et al., 2004; Colbron et al., 2002 ; Dafters and Biello,
2003). Furthermore, disruption of the regular cycle has
been connected to serotonergic mechanisms (Biello
and Dafters, 2001 ; Colbron et al., 2002). Our ﬁnding
of altered 5-HTT densities in the SCN after MDMA
treatment further supports the role of SCN in sleep
disturbances caused by MDMA.
Despite the reduced REM latency, we could not
ﬁnd signiﬁcant changes in the amount of REM sleep
after REM onset. The ﬁring rate of DRN neurons is
almost absent and is also decreased in the MRN
during REM sleep (McGinty and Harper, 1976 ; Portas
et al., 1996 ; Urbain et al., 2006). It is more likely that
during REM latency, before the onset of REM sleep,
the MDMA-induced damage elicits a faster reduction
of the 5-HT input, thus, the threshold will be reached
earlier. The amount of REM sleep does not change
after that since the 5-HT input is absent. Furthermore,
the amount of REM sleep, once initiated, is determined
primarily by homeostatic mechanisms (Wurts and
Edgar, 2000).
Among the nine parameters of NREM sleep, only
three were altered by MDMA treatment and even
these alterations failed to follow the time-course of
serotonergic damage. The most consistent eﬀect was
an increase in delta power during the ﬁrst hours of the
passive phase in NREM sleep. In addition, SWS-1 in
the passive phase was decreased at 21 d. This ﬁnding
is consistent with the increase in delta power caused
by 5-HT2A receptor antagonists (Dugovic et al., 1989;
Monti and Monti, 1999 ; Sebban et al., 2002 ; Ursin,
2002). Interestingly, 5-HT2B and 5-HT2C receptor anta-
gonists fail to cause a similar eﬀect (Kantor et al.,
2002 ; Popa et al., 2005). The present experiments
provide evidence that a partial lesion of the sero-
tonergic system depletes the endogenous 5-HT tone
that physiologically inhibits delta activity during
NREM sleep. The role of tonic inhibition of delta
power by 5-HT through 5-HT2A receptors has been
suggested on the basis of pharmacological studies
(Monti and Monti, 1999 ; Sebban et al., 2002; Ursin,
2002)
Sleep fragmentation, an inverse measure of sleep
continuity, was increased at 7 d after MDMA admin-
istration. Interestingly, this disturbance was normal-
ized by day 21, despite the continuous presence of
serotonergic lesions in all brain areas.
In one study, sleep alterations were compared in
MDMA users and control subjects. Signiﬁcant diﬀer-
ences were found only in NREM sleep parameters.
REM latency was lower by 20% in MDMA users, but
the diﬀerence was not signiﬁcant. The lack of signiﬁ-
cantly decreased REM latency in MDMA users may be
explained by the fact that the time elapsed from the
last ecstasy use was very heterogeneous in the sample
(Allen et al., 1993).
In conclusion, transient changes in the terminal and
cellular regions of the ascending serotonergic system,
and in parallel some altered sleep functions, were
found after a single dose of MDMA. These data pro-
vide further evidence for the connection between
altered serotonergic functions and sleep disturbance.
Despite prolonged serotonergic damage in the hippo-
campus, all functional changes in sleep were normal-
ized together with recovery of ﬁbre density in most
brain areas 180 d after MDMA treatment.
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